CD33 is part of the immunoglobulin superfamily of molecules. In normal cells, CD33 is a myeloid differentiation marker, starting in the very early stages of myeloid cell development. It is expressed on a variety of hematopoietic cells, but not on hematopoietic stem cells or any other cells. Research suggests that CD33 plays a role in inflammation and immune responses.1
CD33 is expressed on nearly all acute myeloid leukemia (AML) cells, making it an ideal target for therapy.1,2 In pediatric trials, AML blasts with high CD33 concentration were associated with poor prognosis, including shorter disease-free intervals and lower overall survival. CD33 can also be detected as a soluble protein and may have prognostic value.1
Search our clinical trials.
CD: cluster of differentiation.
1. Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014;28(4):143-153. 2. Krupka C, Kufer P, Kischel R, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330. Blood. 2014;123(3):356-365.